GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00021819 | Breast | Precancer | cytoplasmic translation | 80/1080 | 148/18723 | 1.59e-59 | 8.54e-56 | 80 |
GO:00226139 | Breast | Precancer | ribonucleoprotein complex biogenesis | 79/1080 | 463/18723 | 2.11e-18 | 1.03e-15 | 79 |
GO:00069799 | Breast | Precancer | response to oxidative stress | 70/1080 | 446/18723 | 1.59e-14 | 4.26e-12 | 70 |
GO:00064578 | Breast | Precancer | protein folding | 43/1080 | 212/18723 | 3.48e-13 | 7.45e-11 | 43 |
GO:00422549 | Breast | Precancer | ribosome biogenesis | 52/1080 | 299/18723 | 7.35e-13 | 1.51e-10 | 52 |
GO:00083809 | Breast | Precancer | RNA splicing | 65/1080 | 434/18723 | 1.27e-12 | 2.53e-10 | 65 |
GO:00434849 | Breast | Precancer | regulation of RNA splicing | 34/1080 | 148/18723 | 2.66e-12 | 4.75e-10 | 34 |
GO:00064179 | Breast | Precancer | regulation of translation | 67/1080 | 468/18723 | 4.71e-12 | 7.64e-10 | 67 |
GO:00457279 | Breast | Precancer | positive regulation of translation | 32/1080 | 136/18723 | 5.89e-12 | 9.27e-10 | 32 |
GO:00003759 | Breast | Precancer | RNA splicing, via transesterification reactions | 52/1080 | 324/18723 | 1.74e-11 | 2.22e-09 | 52 |
GO:00003779 | Breast | Precancer | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 51/1080 | 320/18723 | 3.55e-11 | 4.04e-09 | 51 |
GO:00003989 | Breast | Precancer | mRNA splicing, via spliceosome | 51/1080 | 320/18723 | 3.55e-11 | 4.04e-09 | 51 |
GO:00342509 | Breast | Precancer | positive regulation of cellular amide metabolic process | 33/1080 | 162/18723 | 1.72e-10 | 1.77e-08 | 33 |
GO:00422749 | Breast | Precancer | ribosomal small subunit biogenesis | 21/1080 | 73/18723 | 4.84e-10 | 4.39e-08 | 21 |
GO:00064588 | Breast | Precancer | 'de novo' protein folding | 16/1080 | 43/18723 | 8.14e-10 | 6.92e-08 | 16 |
GO:00003029 | Breast | Precancer | response to reactive oxygen species | 38/1080 | 222/18723 | 1.47e-09 | 1.23e-07 | 38 |
GO:00610778 | Breast | Precancer | chaperone-mediated protein folding | 19/1080 | 67/18723 | 4.22e-09 | 3.28e-07 | 19 |
GO:00510848 | Breast | Precancer | 'de novo' posttranslational protein folding | 14/1080 | 39/18723 | 1.61e-08 | 1.12e-06 | 14 |
GO:00510858 | Breast | Precancer | chaperone cofactor-dependent protein refolding | 13/1080 | 34/18723 | 2.17e-08 | 1.47e-06 | 13 |
GO:00359669 | Breast | Precancer | response to topologically incorrect protein | 29/1080 | 159/18723 | 3.00e-08 | 1.89e-06 | 29 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517114 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0513014 | Liver | NAFLD | Pathogenic Escherichia coli infection | 45/1043 | 197/8465 | 2.31e-05 | 6.88e-04 | 5.54e-04 | 45 |
hsa0481010 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517115 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0513015 | Liver | NAFLD | Pathogenic Escherichia coli infection | 45/1043 | 197/8465 | 2.31e-05 | 6.88e-04 | 5.54e-04 | 45 |
hsa0481011 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0513022 | Liver | Cirrhotic | Pathogenic Escherichia coli infection | 88/2530 | 197/8465 | 6.48e-06 | 6.24e-05 | 3.84e-05 | 88 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481031 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0513032 | Liver | Cirrhotic | Pathogenic Escherichia coli infection | 88/2530 | 197/8465 | 6.48e-06 | 6.24e-05 | 3.84e-05 | 88 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa0513042 | Liver | HCC | Pathogenic Escherichia coli infection | 129/4020 | 197/8465 | 2.02e-07 | 2.50e-06 | 1.39e-06 | 129 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481041 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
F2 | SNV | Missense_Mutation | novel | c.1390N>T | p.Ala464Ser | p.A464S | P00734 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B6-A0RL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
F2 | SNV | Missense_Mutation | rs121918482 | c.1292N>A | p.Arg431His | p.R431H | P00734 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
F2 | SNV | Missense_Mutation | | c.448N>T | p.Ala150Ser | p.A150S | P00734 | protein_coding | tolerated(0.47) | benign(0.06) | TCGA-E2-A15S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
F2 | insertion | In_Frame_Ins | novel | c.1074_1075insACCCAGCATGAGCTTTCCTGGGATTACTCATAT | p.Ser358_Tyr359insThrGlnHisGluLeuSerTrpAspTyrSerTyr | p.S358_Y359insTQHELSWDYSY | P00734 | protein_coding | | | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
F2 | deletion | Frame_Shift_Del | | c.1015_1025delNNNNNNNNNNN | p.Pro340GlufsTer55 | p.P340Efs*55 | P00734 | protein_coding | | | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
F2 | deletion | Frame_Shift_Del | novel | c.204delN | p.Glu69ArgfsTer52 | p.E69Rfs*52 | P00734 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
F2 | SNV | Missense_Mutation | rs144785536 | c.103C>T | p.Arg35Trp | p.R35W | P00734 | protein_coding | tolerated(0.11) | benign(0.093) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
F2 | SNV | Missense_Mutation | novel | c.1755N>T | p.Met585Ile | p.M585I | P00734 | protein_coding | tolerated(0.47) | benign(0.011) | TCGA-EK-A2RE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
F2 | SNV | Missense_Mutation | novel | c.225N>C | p.Glu75Asp | p.E75D | P00734 | protein_coding | deleterious(0.01) | probably_damaging(0.987) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
F2 | SNV | Missense_Mutation | rs775306348 | c.5C>T | p.Ala2Val | p.A2V | P00734 | protein_coding | tolerated_low_confidence(0.14) | benign(0.01) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | FLOVAGATRAN | | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | MPC-0920 | | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | DP-4088 | | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL1615369 | DABIGATRAN ETEXILATE MESYLATE | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | LB-30870 | | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | LEPIRUDIN | LEPIRUDIN | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | SILIBININ | SILIBININ | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | Solulin | | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | SSR-128428 | | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | Lusutrombopag | LUSUTROMBOPAG | |